Ro shifts to dual-track GLP-1 platform
Ro
This was the moment Ro stopped treating obesity as a shortage driven pharmacy arbitrage play, and started acting like a branded access layer for GLP-1 manufacturers. When compounded semaglutide was the only option, Ro mostly won by sourcing cheaper supply and wrapping it in telehealth. Adding Wegovy through a direct NovoCare integration turned Ro into a traffic and care manager for two lanes, branded drug access for patients who want FDA approved manufacturer supply, and compounded options for cash pay patients still optimizing for price or availability.
-
The workflow changed in a concrete way. Patients could consult, get prescribed, pay, and have manufacturer sourced Wegovy shipped without leaving Ro’s app. NovoCare handled the branded channel behind the scenes, while Ro kept the patient relationship, the membership fee, and the ongoing titration and monitoring layer.
-
This also reduced Ro’s exposure to the FDA crackdown on compounding after shortages eased in early 2025. A dual track model let Ro keep serving denied or price sensitive patients with compounded GLP-1s, while shifting a growing share of volume to compliant branded supply. By mid 2025, more than half of Ro’s GLP-1 business was already flowing through manufacturer cash pay channels.
-
Competitively, this moved Ro closer to Noom and Hims & Hers, which were also racing to bundle obesity medication with software and coaching, but Ro’s edge was deeper care operations. Ro Body adds labs, dose logging, side effect monitoring, messaging, and pharmacy fulfillment, which matters more in GLP-1s than in simpler telehealth categories like ED or hair loss.
The direction of travel is toward obesity platforms that look less like online pharmacies and more like operating systems for long term medication management. As branded GLP-1 supply becomes easier to access and price competition intensifies, Ro’s advantage will come from owning the care workflow around the drug, not from the drug markup itself.